

BIRMINGHAM, AL, UNITED STATES, May 11, 2026

[/EINPresswire.com/](https://EINPresswire.com/) -- [Diamond Therapeutics Inc.](#), a clinical-stage drug development company that advances innovative mental health therapeutics using psilocybin and other novel neuroplastogens, has received a multi-million dollar funding award from the Advanced Research Projects Agency for Health (ARPA-H) for the company's phase 2 clinical trial of a treatment for generalized anxiety disorder (GAD).

The funding from ARPA-H, an independent agency within the



ARPA-H funding will accelerate our efforts to advance an innovative therapeutic with potential to bring relief to millions of people worldwide who are suffering from generalized anxiety disorder."

— *Michael McDonnell, Chief Medical Officer, Diamond Therapeutics*

"ARPA-H funding will accelerate our efforts to advance an innovative therapeutic that has the potential to bring relief to millions of people worldwide who are suffering from generalized anxiety disorder," said Michael McDonnell, Chief Medical Officer of Diamond. "Tactical Mind Solutions will play a key role in our expanded clinical trials, along with other partners."



Diamond Therapeutics - ARPA-H Funding Graphic

U.S. Department of Health and Human Services, will help support the expansion of Diamond's ongoing study in Canada to the U.S., in partnership with St. Petersburg, Florida-based [Tactical Mind Research Coalition](#). Diamond, through its U.S. operations, headquartered in Birmingham, Alabama, will contribute data from its trial under ARPA-H's Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) initiative. [EVIDENT will collectively fund up to \\$139.4 million](#) to help spur new, effective therapies for behavioral health.

"We thank ARPA-H for supporting our work and, in turn, look forward to providing data in support of the Agency's efforts to validate the effectiveness and safety of rapid-acting therapies including psilocybin," said Judy Blumstock, Founder and CEO of Diamond Therapeutics.

More From This Source

[Diamond Therapeutics Receives Multi-Million Dollar US Government Funding for Phase 2 Clinical Trial of Anxiety Treatment](#)

[Diamond Therapeutics Welcomes White House Executive Order on Research into Psychedelics for Mental Health Treatment](#)

[View All Stories From This Source](#)